Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: combjelly who wrote (889604)	9/23/2015 12:05:03 AM
From: i-node	Respond to of 1576627

Yeah, and as usual you are clueless. "Instead, the most promising solution is probably pushing on regulators, not singling out pharma companies. Writing in the NEJM last year, Jonathan Alpern and coauthors suggested that FDA needed to dramatically speed up its process to encourage new generic manufacturers; the agency on average needs 10 months just to process a new application to produce a drug. “[W]e believe that special pathways should be created to promote competition and permit the private market to function more efficiently,” Alpern and his coauthors wrote. Getting FDA to change its regulations is a slow process. There won’t be any TV-ready villains; just rounds of public comment and dry testimony. And the rules won’t be fixed by a few days of negative headlines." Which, now that I think about it, is precisely what I told you, isn't it?